drugset / Trial / NCT02186769

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769

Phase 1 Completed 16 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A review of the amount of drug in your blood over time.

Timeline

Start
2014-07
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified 25 mg Intramuscular
Comparator Risperidone Other / unclassified 50 mg Intramuscular